Bristol-Myers Squibb to Post Select Investigational Compound Data Updates on Company Website

NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) will begin posting updates about select Phase 1 and 2 investigational compounds on the company website at www.bms.com/research/investigational. The updates will communicate an overview of new data presented at medical meetings or data published in scientific journals. The first update will be posted on Saturday, April 17, 2010.

Media and investors interested in receiving notifications when investigational compound updates are posted may subscribe to Bristol-Myers Squibb’s “Investigational Compound News” RSS feed at www.bms.com/news/pages/rss_alerts.aspx.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com.



CONTACT:

Bristol-Myers Squibb Company
Media:
Sonia Choi, 609-252-5132
[email protected]
or
Investors:
John Elicker, 609-252-4611
[email protected]

KEYWORDS:   United States  North America  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Pharmaceutical  Other Health  General Health

MEDIA:

Logo
 Logo

Suggested Articles

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.

The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.